An algorithm to compare two‐dimensional footwear outsole images using maximum cliques and speeded‐up robust feature

Footwear examiners are tasked with comparing an outsole impression (Q) left at a crime scene with an impression (K) from a database or from the suspect\u27s shoe. We propose a method for comparing two shoe outsole impressions that relies on robust features (speeded‐up robust feature; SURF) on each impression and aligns them using a maximum clique (MC). After alignment, an algorithm we denote MC‐COMP is used to extract additional features that are then combined into a univariate similarity score using a random forest (RF). We use a database of shoe outsole impressions that includes images from two models of athletic shoes that were purchased new and then worn by study participants for about 6 months. The shoes share class characteristics such as outsole pattern and size, and thus the comparison is challenging. We find that the RF implemented on SURF outperforms other methods recently proposed in the literature in terms of classification precision. In more realistic scenarios where crime scene impressions may be degraded and smudged, the algorithm we propose—denoted MC‐COMP‐SURF—shows the best classification performance by detecting unique features better than other methods. The algorithm can be implemented with the R‐package shoeprintr

A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation

<p>Abstract</p> <p>Background</p> <p>New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according to existing guidelines for type II diabetes. To date, only a few trials have studied antidiabetic drugs in patients with NODAT. Vildagliptin is a novel dipeptidyl peptidase-4 (DPP-4) inhibitor that improves pancreatic islet function by enhancing both α- and β-cell responsiveness to increased blood glucose. Experimental data show potential protective effects of DPP-4 inhibitors on islet function after exogenous stress stimuli including immunosuppressants. Therefore, the therapy of NODAT with this class of compounds seems attractive. At present, vildagliptin is used to treat type II diabetes as monotherapy or in combination with other antidiabetic drugs, since that it efficiently decreases glycated hemoglobin (HbA1c) values. Additionally, vildagliptin has been shown to be safe in patients with moderately impaired kidney function. This study will evaluate the safety and efficacy of vildagliptin monotherapy in renal transplant recipients with recently diagnosed NODAT.</p> <p>Methods/Design</p> <p>This study is a randomized, placebo-controlled, double-blind, prospective phase II trial. Using the results of routinely performed oral glucose tolerance tests (OGTT) in stable renal transplant patients at our center, we will recruit patients without a history of diabetes and a 2 h glucose value surpassing 200 mg/dl (11.1 mmol/l). They are randomized to receive either 50 mg vildagliptin or placebo once daily. A total of 32 patients with newly diagnosed NODAT will be included. The primary endpoint is the difference in the 2 h glucose value between baseline and the repeated OGTT performed 3 months after treatment start, compared between the vildagliptin- and the placebo-group. Secondary endpoints include changes in HbA1c and fasting plasma glucose (FPG). The safety of vildagliptin in renal transplant patients will be assessed by the number of symptomatic hypoglycemic episodes (glucose <72 mg/dl or 4 mmol/l), the number of adverse events, and possible medication-associated side-effects.</p> <p>Discussion</p> <p>NODAT is a severe complication after kidney transplantation. Few trials have assessed the safety and efficacy of antidiabetic drugs for these patients. The purpose of this study is to assess the safety and efficacy of vildagliptin in renal transplant patients with NODAT.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov NCT00980356</p

Simultaneous Determination of Oxysterols, Cholesterol and 25-Hydroxy-Vitamin D3 in Human Plasma by LC-UV-MS

<div><p>Background</p><p>Oxysterols are promising biomarkers of neurodegenerative diseases that are linked with cholesterol and vitamin D metabolism. There is an unmet need for methods capable of sensitive, and simultaneous quantitation of multiple oxysterols, vitamin D and cholesterol pathway biomarkers.</p><p>Methods</p><p>A method for simultaneous determination of 5 major oxysterols, 25-hydroxy vitamin D3 and cholesterol in human plasma was developed. Total oxysterols were prepared by room temperature saponification followed by solid phase extraction from plasma spiked with deuterated internal standards. Oxysterols were resolved by reverse phase HPLC using a methanol/water/0.1% formic acid gradient. Oxysterols and 25-hydroxy vitamin D3 were detected with atmospheric pressure chemical ionization mass spectrometry in positive ion mode; in-series photodiode array detection at 204nm was used for cholesterol. Method validation studies were performed. Oxysterol levels in 220 plasma samples from healthy control subjects, multiple sclerosis and other neurological disorders patients were quantitated.</p><p>Results</p><p>Our method quantitated 5 oxysterols, cholesterol and 25-hydroxy vitamin D3 from 200 μL plasma in 35 minutes. Recoveries were >85% for all analytes and internal standards. The limits of detection were 3-10 ng/mL for oxysterols and 25-hydroxy vitamin D3 and 1 μg/mL for simultaneous detection of cholesterol. Analytical imprecision was <10 %CV for 24(S)-, 25-, 27-, 7α-hydroxycholesterol (HC) and cholesterol and ≤15 % for 7-keto-cholesterol. Multiple Sclerosis and other neurological disorder patients had lower 27-hydroxycholesterol levels compared to controls whereas 7α-hydroxycholesterol was lower specifically in Multiple Sclerosis.</p><p>Conclusion</p><p>The method is suitable for measuring plasma oxysterols levels in human health and disease. Analysis of human plasma indicates that the oxysterol, bile acid precursors 7α-hydroxycholesterol and 27-hydroxycholesterol are lower in Multiple Sclerosis and may serve as potential biomarkers of disease.</p></div

Comparison of the assay to external reference materials.

<p>The oxysterol reference materials were from Referenzinstitut für Bioanalytik and the vitamin D3 reference material was from The National Institute of Standards and Technology. 50pct; 50th percentile of the corresponding LC-MS sub-collective</p><p>Comparison of the assay to external reference materials.</p

LC-MS-PDA chromatogram of standards.

<p>The top panel shows the chromatogram of each selected ion-monitoring (SIM) channel with each analyte identified at the peak apex. MS Off/MS On indicated the activation points for the flow control valve. The bottom panel shows the PDA Chromatogram at 204 nm.</p

Side-chain oxygenated oxysterol levels in patient groups.

<p>Distribution of 24-hydroxy cholesterol (24HC; Fig 2A), 25-hydroxy cholesterol (25HC; Fig 2C) and 27-hydroxy cholesterol (27HC; Fig 2E) for healthy controls (HC), multiple sclerosis (MSC) and other neurological diseases (OND). The results in Fig 2B, 2D and 2F correspond to the oxysterols in Fig 2A, 2C and 2E, respectively, but are normalized to total cholesterol (TC) levels. The dot-plots of individual patients are superimposed on the box plots. The solid line in the box plots are the median, the box delineates upper and lower quartiles and the error bar represents the range. Panel E for 27HC and Panel F for 27HC-TC ratio contains the p-value from the Kruskal-Wallis test in the main body. The inset contains a bar graph and p-values from follow-up Mann-Whitney tests.</p